Compare YRD & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | IMRX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.4M | 320.3M |
| IPO Year | 2015 | 2021 |
| Metric | YRD | IMRX |
|---|---|---|
| Price | $3.60 | $4.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 34.6K | ★ 713.7K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 12.36% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $1.10 |
| 52 Week High | $7.68 | $10.08 |
| Indicator | YRD | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 41.94 |
| Support Level | $3.58 | $4.49 |
| Resistance Level | $3.98 | $5.36 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 19.15 | 9.57 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.